Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: March 3, 2014

Today's headlins include stories detailing ongoing challenges with state-run exchanges as well as previews of what's next regarding the federal budget process.

3 Mar 2014

Longer looks: A doctor struggles with new health system; how to reduce end-of-life costs; fighting cancer with aspirin

I know how lucky I am to be a patient who happens to also work in the healthcare system. ... Initially, I had to use antibiotic drops every hour. But my insurance would only cover one three-milliliter bottle every three weeks. Each bottle not covered by insurance cost me $130. ... My own experience makes me fear that for many Americans, health insurance may not necessarily equal health care. Access and cost will still remain barriers - and can be difficult to surmount for many (Dr. Helen Ouyang, 2/24)

28 Feb 2014

Waiting room time helps in effective screening for depression and anxiety

A new study in General Hospital Psychiatry finds patients visiting the hospital for a variety of ailments can be easily screened for depression and anxiety as they wait for care, information that can then be sent immediately to their doctor to address.

27 Feb 2014

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human antibodies that could hold the key to a vaccine for the world's most widespread mosquito-borne disease.

27 Feb 2014

UNC receives $40M for clinical trials unit devoted to HIV/AIDS treatment, prevention and research

The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.

27 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Scientists discover how viral DNA of HBV can be degraded in cell nucleus

Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.

24 Feb 2014

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Researchers have long known that people with autoimmune diseases, such as hepatitis, type 1 diabetes, multiple sclerosis and psoriasis, are at greater risk of developing schizophrenia.

24 Feb 2014

Social/behavioral intervention strategies may help drug users avoid injection-related HCV, HIV infections

Despite a number of social/behavioral intervention and educational programs, the spread of hepatitis C (HCV) in people who inject drugs (PWIDs) remains a chronic problem.

24 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Major gaps persist in workplace protection against TB, HIV and hepatitis in South Africa

A large-scale survey of South African healthcare workers has revealed major gaps in workplace protection against tuberculosis, HIV and hepatitis, according to a University of British Columbia health researcher.

16 Feb 2014

Viewpoints: Decoupling jobs and insurance; overblown fear: Medicaid willl take my house

Three blog posts and a column should probably suffice to cover the debate over Obamacare and work incentives, but I don't want to let the topic drop without first stepping back and talking about the actual health policy disagreement here.

14 Feb 2014

Persons with severe symptoms of mental illness are at higher risk for being HIV-infected

People receiving mental health care are up to four times more likely to be infected with HIV than the general population, according to a new study published Feb. 13 in the American Journal of Public Health from researchers at Penn Medicine and other institutions who tested over 1,000 patients in care in Philadelphia and Baltimore.

14 Feb 2014

Colour-changing ABC Syringe shortlisted for 2014 World Design Impact Prize

University of Huddersfield lecturer Dr David Swann's design for a syringe that changes colour in order to deter its re-use - with the possibility of spreading dangerous infection - has already earned global interest. Now the project's profile will be raised higher still, following its shortlisting for a second major design award.

11 Feb 2014

Study findings suggest potential targets for treating HCV

The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus' attempt to weaken the attack on it.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections.

7 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Alabama experts develop living document that includes new therapies for Hepatitis C virus

When treatment guidelines for a particular disease emerge, they are often published in a peer-reviewed medical journal, which can take up to three years. One University of Alabama at Birmingham infectious diseases expert recently helped develop new Hepatitis C virus (HCV) guidelines that can be updated and published as new data emerge and new therapies are approved.

5 Feb 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: March 3, 2014

Longer looks: A doctor struggles with new health system; how to reduce end-of-life costs; fighting cancer with aspirin

Waiting room time helps in effective screening for depression and anxiety

Researchers discover new target for human antibodies that holds key to vaccine for dengue

UNC receives $40M for clinical trials unit devoted to HIV/AIDS treatment, prevention and research

FDA approves KALYDECO for people with cystic fibrosis

Scientists discover how viral DNA of HBV can be degraded in cell nucleus

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Social/behavioral intervention strategies may help drug users avoid injection-related HCV, HIV infections

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Major gaps persist in workplace protection against TB, HIV and hepatitis in South Africa

Viewpoints: Decoupling jobs and insurance; overblown fear: Medicaid willl take my house

Persons with severe symptoms of mental illness are at higher risk for being HIV-infected

Colour-changing ABC Syringe shortlisted for 2014 World Design Impact Prize

Study findings suggest potential targets for treating HCV

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

Researchers design new vaccine for human-infecting respiratory syncytial virus

Alabama experts develop living document that includes new therapies for Hepatitis C virus

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Hepatitis C News and Research

Latest Hepatitis C News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in